{"id":"W3157098966","doi":"10.1097/hs9.0000000000000562","title":"Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial","year":2021,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sierra Oncology; Incyte; Gilead Sciences; CTI Biopharma; Celgene; Sanofi; Bristol-Myers Squibb","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Quality of life (healthcare); Internal medicine; Clinical trial; Population; Physical therapy; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001037905,0.0004954842,0.001017144,0.0001897388,0.0002039885,0.0005229745,0.0002525325,0.0005387458,0.001417471],"category_scores_gemma":[0.0006727698,0.000142869,0.001129915,0.000208387,0.0001919923,0.0003117271,0.0001789181,0.001101698,0.00017559],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002635874,"about_ca_system_score_gemma":0.0003384862,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005134595,"about_ca_topic_score_gemma":0.001671045,"domain_scores_codex":[0.9997943,0.00008926646,0.0000235437,0.00002506333,0.00002892337,0.00003884307],"domain_scores_gemma":[0.9996756,0.00006041888,0.00009779327,0.00002326649,0.00002486837,0.0001179088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6003469,0.02209034,0.04947812,0.001502503,0.005224728,0.0004436986,0.0002302868,0.003466536,0.02653388,0.0002271888,0.008682993,0.2817727],"study_design_scores_gemma":[0.4202393,0.2889195,0.267432,0.0002396522,0.003632384,0.00134687,0.0001307368,0.005720077,0.004980528,0.000272142,0.007006275,0.00008038696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921947,0.005125985,0.000101273,0.0003050153,0.00007806822,0.0002483093,0.0006625068,0.00003732443,0.001246914],"genre_scores_gemma":[0.9949535,0.001761907,0.0002973619,0.0004529205,0.0001227023,0.0001713253,0.001661596,0.000003771894,0.0005748699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001417471,"threshold_uncertainty_score":0.005489051,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02729231896859579,"score_gpt":0.2889486548959623,"score_spread":0.2616563359273665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}